紫杉醇联合卡铂治疗复发性卵巢癌的临床观察  

Clinical Observation of Paclitaxel Combined with Carboplatin in the Treatment of Recurrent Ovarian Cancer

作　　者：杨雪梅[1] 黎世蓉[1] 

机构地区：[1]成都市第五人民医院肿瘤科,成都611130

出　　处：《肿瘤预防与治疗》2008年第3期289-290,279,共3页Journal of Cancer Control And Treatment

摘　　要：目的：观察紫杉醇联合卡铂（IP方案）治疗晚期复发性卵巢癌的有效性和安全性。方法：40例复发性卵巢癌患者，应用，IP方案（紫杉醇150mg／m^2，第1天，卡铂AUC=5，第1天，每21天-28天）化疗，评价近期疗效及其毒性，观察QOL和KPS评分变化情况。结果：38例可评价疗效，其中CR8例，PR18例，SD8例，PD4例，RR（CR＋PR）为68．4％，QOL评分由治疗前平均35．6分提高到54．7分，KPS评分由治疗前平均78．7分提高到92．4分。主要毒副反应为骨髓抑制、肾毒性、肌肉关节痛、神经毒性、脱发和胃肠道反应。结论：TP方案治疗晚期复发性卵巢癌疗效确切，能改善患者的生活质量，毒副反应较轻，值得临床推广。Objective： To observe the efficacy and security of paclitaxel combined with carboplatin （TP regimen） in patients with advanced recurrent ovarian cancer. Methods： Forty cases of advanced recurrent ovarian cancer received chemotherapy with TP regimen （pacilitaxel 150mg/m^2 , d1 , carboplatain AUC = 5, d1 , every 21-28 days）. Short-term curative effect and toxicity were evaluated. Changes in quality of life（QOL） and Karnofsky scores were observed. Results： Efficacy of thlrty-elght patients were evaluated. Eight patients achieved complete response（ CR）, eighteen patients achieved partial response（ PR）, eight patients achieved stable disease（SD） and four patients achieved progressed disease（PD）. The overall response rate（ RR = CR ＋ PR） was 68.4%. The average QOL score increased from 35.6 points before treatment to 54.7 points after treatment. The average Karnofsky score increased from 78. 7 points before treatment to 92.4 points after treatment. The major adverse effects were bone marrow depression, renal toxicity, courbature, arthralgia, neurotoxicity, alopecie and gastrointestinal tract response. Conclusion： TP regimen was an effective way to treat ad- vanced recurrent ovarian cancer. It can also improve llfe quality of patients with mild adverse effect. Therefore, TP regimen was recommended to be applied clinically.

关 键 词：卵巢癌/复发性 化学治疗 紫杉醇 卡铂 

分 类 号：R737.31[医药卫生—肿瘤] R730.53[医药卫生—临床医学]